Oncternal Therapeutics Valuation
Based on Macroaxis valuation methodology, the company cannot be evaluated at this time. Oncternal Therapeutics recent Real Value cannot be determined due to lack of data. The prevailing price of Oncternal Therapeutics is $0.0. Our model determines the value of Oncternal Therapeutics from analyzing the company fundamentals such as Current Valuation of (12.83 M), return on equity of -1.5, and Shares Owned By Insiders of 9.23 % as well as examining its technical indicators and probability of bankruptcy.
Oncternal Therapeutics Total Value Analysis
Oncternal Therapeutics is now forecasted to have valuation of (12.83 M) with market capitalization of 1.56 M, debt of 318 K, and cash on hands of 78.9 M. The negative valuation of Oncternal Therapeutics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Oncternal Therapeutics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(12.83 M) | 1.56 M | 318 K | 78.9 M |
Oncternal Therapeutics Investor Information
The company has price-to-book ratio of 0.17. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Oncternal Therapeutics recorded a loss per share of 11.69. The entity last dividend was issued on the 10th of June 2019. The firm had 1:20 split on the 8th of January 2024. Based on the key indicators related to Oncternal Therapeutics' liquidity, profitability, solvency, and operating efficiency, Oncternal Therapeutics is not in a good financial situation at this time. It has a very high probability of going through financial hardship in April.Oncternal Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Oncternal Therapeutics has an asset utilization ratio of 2.14 percent. This implies that the Company is making $0.0214 for each dollar of assets. An increasing asset utilization means that Oncternal Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Oncternal Therapeutics Ownership Allocation
Oncternal Therapeutics holds 9.23 pct. of its outstanding shares held by insiders and 12.07 pct. owned by third-party entities.Oncternal Therapeutics Profitability Analysis
The company reported the previous year's revenue of 785 K. Net Loss for the year was (39.48 M) with loss before overhead, payroll, taxes, and interest of (31.49 M).Oncternal Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Oncternal Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 2.9 M |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Other Consideration for investing in Oncternal Stock
If you are still planning to invest in Oncternal Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Oncternal Therapeutics' history and understand the potential risks before investing.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |